Which company’s drug information is Brivaracetam?

Brivaracetam/Brivaracetam (Brivaracetam), trade nameBriviact, is developed and produced by the Belgian pharmaceutical company UCB (UCB Pharma). UCB is a leading global biopharmaceutical company headquartered in Brussels, Belgium, dedicated to developing innovative medicines to address patients' unmet medical needs in the fields of neurological and immunology. Founded in 1908, UCB has a century-old history. It is a multinational enterprise with operations in many countries and regions around the world.

UCB's product lines are mainly concentrated in the fields of neuroscience, immunology and biopharmaceuticals. Brivaracetam, as one of its representative drugs in the field of neuroscience, is specially used to treat epilepsy. Brivaracetam is approved in many countries and territories around the world for the treatment of partial-onset seizures, particularly in patients for whom other medications have not responded satisfactorily. It is a newer anti-epileptic drug. Its mechanism of action is mainly by binding and regulating the neurotransmitter system, especially by binding to synaptic vesicle protein 2A (SV2A), to reduce the abnormal excitability of neurons, thereby controlling epileptic seizures.

In addition to Brivaracetam,UCB also develops and produces a number of drugs for the treatment of neurological diseases, such as Ropinirole and Fampyra, drugs for the treatment of Parkinson's disease and amyotrophic lateral sclerosis (ALS). UCB has a strong R&D team and production capabilities worldwide, continues to invest a lot of resources in drug research and development, and is committed to solving the treatment problems of diseases related to the nervous system and immune system.

As one of the core products ofUCB, Brivaracetam has been widely used in the treatment of epilepsy due to its low side effects and high efficacy since its launch. Especially in the treatment of epilepsy, brivaracetam, as a second-generation anti-epileptic drug, has milder side effects than traditional anti-epileptic drugs and can take effect in a shorter period of time to help patients control epileptic seizures. The launch of Brivaracetam has also enabled UCB to occupy an important position in the global anti-epileptic drug market.

Reference materials:https://www.drugs.com/brivaracetam.html